The side effects of Semax can include: * Headaches * Irritability * Dizziness * Nausea * Agitation * Insomnia * Changes in blood pressure
Semax exhibits a relatively mild side-effect profile based on available research. Most reported issues are mild and transient in nature. However, the evidence base primarily comes from animal studies and a limited number of clinical trials in humans conducted in Russia. No large, long-term safety studies have been published in Western peer-reviewed literature to date, meaning the full picture of Semax's long-term effects in the human body remains incomplete.
What we know comes from decades of Russian clinical use, a handful of published human trials, and extensive animal studies. Collectively, this evidence base does not point to significant safety signals – but it does not provide the level of assurance associated with fully approved medicines. This is an important distinction.
The most commonly reported side effects in clinical use in humans involve mild irritation at the site of administration. With standard nasal spray - where the solution is administered directly into the nasal cavity - some users experience mild discomfort, brief stinging, or general nasal irritation. Beyond these local effects, some patients in clinical stroke trials reported minor reactions, though overall tolerability was described as good across various patient groups, including the elderly [1].
In one of the early clinical trials, the first Semax injection caused brief episodes of atypical brain electrical activity, detected by EEG, in some patients with post-traumatic brain injury after hypoxia. This prompted the authors to recommend monitoring brain electrical activity during the first administration of Semax in this specific group of patients [2]. This finding is of importance for clinical practice, however, it exclusively concerns patients with pre-existing brain damage and should not be directly extrapolated to healthy users.
Does Semax cause headaches?
Headache is not a clearly reported side effect in the published clinical literature for Semax. However, the lack of reporting does not definitively rule it out – the available human studies were not designed to systematically track all adverse events according to the standards of modern drug safety trials.
The same intranasal route of administration – delivering a liquid solution into the nasal cavity – may occasionally cause mild discomfort or a feeling of pressure in the head, resulting from the mechanical process of administration. Some users may describe this as a headache. No published study has demonstrated headache as a frequent or clinically significant adverse event following the use of Semax.
In online nootropic communities, anecdotal reports of headaches have emerged among some users, but these cannot be systematically evaluated – they may reflect individual variability, differences in product quality, or interactions with other concurrently used substances.
Does Semax cause nausea?
Nausea is not a documented side effect in the published research literature concerning Semax. Animal studies on the effects of Semax on the digestive system suggest the opposite effect – Semax protected the gastric mucosa from damage induced by alcohol, immobilisation stress, and non-steroidal anti-inflammatory drugs, and also accelerated the healing of existing gastric ulcers [3], [4]. In clinical studies of patients with gastric ulcer disease receiving Semax as a supplement to standard therapy, the peptide was well tolerated with no reported gastrointestinal problems [5].
The absence of nausea in published reports is consistent with Semax's lack of hormonal activity and its non-stimulatory pharmacological profile. However, it is worth noting that systematic monitoring for nausea was not the primary focus in most studies, so mild nausea in some individuals cannot be entirely ruled out.
Does Semax affect blood pressure?
The effect of Semax on blood pressure is not a serious safety concern based on available evidence, although the picture is complex. In a rat model of myocardial infarction, Semax did not directly affect overall heart function or mean blood pressure at the tested doses. However, it partially prevented increases in left ventricular end-diastolic pressure – a pressure that rises abnormally when the heart is under stress – and improved structural cardiac regeneration after infarction [6].
In a separate cardiological study, Semax reduced the density of sympathetic nerve endings – nerve fibres that transmit stress signals – in the arteries of rats following a heart attack, and it also decreased the sensitivity of arterial vessels to nerve stimulation and norepinephrine [7]. Theoretically, these effects would lean towards a moderate reduction in blood pressure rather than an increase.
Semax's anti-stress and antithrombotic properties—including the prevention of stress-induced blood coagulation—suggest an overall cardiovascularly protective rather than destabilising profile [8]. However, no dedicated human study has directly measured Semax's impact on blood pressure as a primary endpoint. Individuals with cardiovascular disease should exercise caution and consult their physician.
Does Semax affect blood sugar levels?
There is limited but significant evidence that Semax may affect blood sugar and fat metabolism. In a study of rats with experimentally induced diabetes, Semax at a dose of 200 micrograms per kilogram corrected disordered lipid metabolism – it lowered total cholesterol, triglycerides, and LDL, while increasing HDL – although the effect was less pronounced than with the comparator drug [9].
In patients with psoriasis who also had metabolic syndrome – encompassing elevated sugar levels, an abnormal lipid profile, and excess abdominal fat – adding Semax to standard treatment resulted in a significant reduction in cholesterol, triglycerides, and LDL compared to standard therapy alone [10].
These results suggest metabolic effects worth monitoring, particularly in individuals with diabetes or metabolic disorders. However, no dangerous fluctuations in blood sugar were observed in healthy individuals. People with diabetes or metabolic disorders should be aware of these potential effects and consult a doctor before considering the use of Semax.
Psychological side effects of Semax include: * Dizziness * Headaches * Irritability * Anxiety * Insomnia * Agitation
Psychological side effects of Semax documented in the research literature are generally mild. In many cases, these are desirable rather than undesirable effects – such as reduced anxiety, improved mood, and increased alertness. The only psychological effects that might be considered truly undesirable in healthy individuals are potential over-stimulation or heightened vigilance in some users, although this has not been systematically documented in clinical studies.
In an EEG study in healthy volunteers, Semax induced changes in brain electrical activity patterns [11], which were not, however, associated with any reported symptoms or discomfort. The antidepressant and anxiolytic effects documented in animal studies are generally considered beneficial [12]. In sensitive individuals, however, any factor modulating serotonin and dopamine activity could theoretically affect mood in an unpredictable way.
No published study has reported serious psychiatric adverse events — such as psychosis, mania, or severe anxiety — after administration of Semax in either animals or humans.
Is Semax safe?
Based on available research, Semax appears to be well-tolerated in the short term. No serious adverse events have been reported in human clinical trials published to date. However, it cannot be described as definitively safe – long-term safety data in humans simply does not exist in sufficient quantity or quality to justify such a statement.
That's an important distinction. A lack of reported serious harm in limited studies is not the same as proven safety. Semax has been used clinically in Russia since the 1990s for stroke and cerebrovascular diseases—and no serious safety signals have emerged in Russian medical literature during that time. A review of the 15-year development period for Semax, published in 1997, explicitly stated that in all clinical cases studied, the peptide showed positive effects and in no case did it cause negative side effects or complications associated with its administration [1]. This is an encouraging historical safety record, but it originates from an era and regulatory environment with different standards for tracking and reporting adverse events than those required today.
Is Semax well tolerated?
Clinical evidence consistently describes Semax as well-tolerated across various patient populations, including elderly patients post-stroke. In a clinical trial of cerebrovascular insufficiency involving 187 patients, Semax was particularly well-tolerated by older individuals as well, with only a small percentage of side effects reported [13].
In a study of acute ischaemic stroke, 30 patients received Semax as part of intensive combination therapy without reporting any serious adverse reactions attributable to the peptide [14]. In a study of motor neuron disease, Semax was administered intranasally for two ten-day courses to medically generally unstable patients, with no serious adverse events noted [15].
These observations are consistent in many clinical contexts. However, all studies were relatively small, and none was specifically designed or statistically powered to detect rare adverse events that may only become apparent in larger populations.
In preclinical safety studies, Semax and related peptides did not induce toxic effects on mouse embryonic stem cells over a wide range of concentrations from 0.1 to 10 micromoles [16], suggesting a lack of embryotoxic effects in cellular models. However, these results cannot be directly extrapolated to the safety of use in human pregnancy.
What are the risks of using Semax?
Identifiable risks of Semax based on current evidence include: local nasal irritation when administered intranasally, potential interactions with cardiovascular medications or conditions due to effects on vascular tone and blood clotting, the possibility of unpredictable reactions in individuals with certain neurological or psychiatric conditions, and the general risks associated with any compound whose long-term effects in humans have not been fully characterised.
The discovery that Semax occasionally induced short-term EEG changes in patients after hypoxic brain injury [2] suggests that individuals with pre-existing seizure disorders or significantly impaired brain function should approach it with particular caution and only under direct medical supervision.
Semax also exhibits copper-chelating properties – it can bind copper ions and extract them from copper-protein complexes in the body [17]. While this might be beneficial in the context of Alzheimer's pathology, it could theoretically affect copper-dependent biochemical processes with prolonged use, as copper is an essential mineral involved in many normal biological functions. However, no studies have reported copper deficiency or associated adverse effects following Semax administration.
Is Semax safe for long-term use?
No published studies have directly assessed the long-term safety of using Semax for months or years in humans. This is one of the most significant gaps in the entire research literature concerning Semax.
Studies on chronic administration in animals — typically lasting days to weeks, rather than months — have not revealed progressive toxicity, organ damage, or worsening outcomes with continued use [12], [18]. Rats receiving repeated doses of Semax exhibited sustained behavioural benefits without signs of tolerance or harm. The rapid enzymatic breakdown of Semax — into biologically active but non-accumulating fragments — makes its accumulation in tissues over time pharmacokinetically unlikely.
However, a lack of toxicity data in short animal studies does not substitute for proper long-term human safety studies. Such studies have not been conducted. Anyone considering long-term use of Semax is acting far outside the scope of what published scientific evidence can confirm in terms of safety.
Kto nie powinien stosować Semax?
Based on available evidence and sound medical caution, certain groups should avoid Semax or use it only under direct medical supervision.
Pregnant and breastfeeding women should avoid it, as there is no reproductive and developmental safety data in humans, and peptides that cross the blood-brain barrier could theoretically affect foetal or infant brain development. Children and adolescents should also avoid it, as the developing brain may respond differently to compounds affecting neurotrophic factors and neurotransmitter systems, and no paediatric safety data exist.
People with seizure disorders or epilepsy should exercise particular caution due to EEG changes observed in some patient groups [2]. Individuals taking anticoagulant medications should be aware of the documented effects of Semax on blood clotting and fibrinolysis [8], as there is a theoretical risk of interaction. Those hypersensitive to any component of Semax should avoid it.
Because Semax is not an approved medication in most countries, there are no official contraindication guidelines from regulatory agencies. The above precautions are based on pharmacological reasoning from published studies rather than official prescribing recommendations.
What does research say about the safety of Semax in specific organ systems?
Research into the effects of Semax on individual organ systems does not reveal any clear signs of toxicity in any specific system.
In the liver, Semax exerted a protective effect on liver cells under both acute and chronic stress conditions, normalising liver enzyme levels and restoring normal protein synthesis [19], [20]. These results are consistent with organ protection, not toxic damage.
In the colon, Semax at appropriate doses prevented stress-induced deterioration of the intestinal lining and maintained healthy gut bacteria populations [21], again suggesting a protective rather than harmful effect on gastrointestinal tissue.
In the heart, Semax demonstrated cardioprotective effects in myocardial infarction models, protecting cardiac muscle cells and limiting harmful sympathetic nervous system overactivity [6], [7].
In aggregate, organ-level evidence does not indicate toxicity in any specific system at the doses used in the studies. However, formal dose-escalation toxicology studies and dedicated human organ safety investigations remain unpublished.
Does Semax cause addiction?
Semax does not appear to be habit-forming based on its known pharmacological properties and the absence of addiction-related behaviours in published research literature. Addiction typically involves direct and robust stimulation of the brain's reward system through a large release of dopamine—particularly in an area called the nucleus accumbens—which creates reinforcing, compulsive drug-seeking behaviours.
Semax does not directly trigger dopamine release under normal conditions. It only enhances dopaminergic responses that are already occurring in response to other stimuli [22]. No studies have reported reward-related behaviours, self-administration, or conditioned place preference—a standard animal addiction test—following Semax administration.
Semax's mechanism of action – through the increase of neurotrophic factors, modulation of gene expression, and fine-tuning of neurotransmitter systems – is fundamentally different from the mechanisms driving substance addiction, such as to opioids, stimulants, or benzodiazepines.
One discovery is worth noting: Semax inhibits enzymes that break down enkephalins – the brain's own naturally occurring pain-relieving peptides – in human blood [23]. Modulation of the enkephalinergic system may contribute to enhancing effects for some compounds. However, the indirect and limited nature of this effect, combined with the absence of any signs of addiction over decades of clinical and research use, does not justify classifying Semax as a substance with significant addictive potential.
The recent identification of the μ-opioid receptor as a molecular target of Semax in spinal cord injury research [24] adds theoretical considerations. However, the context is mechanistically distinct from opioid addiction: Semax interacts with this receptor to regulate cellular waste processing and neuroprotection, rather than inducing analgesia or euphoria associated with addictive opioids.
Does Semax cause tolerance?
No published studies have reported the development of tolerance when using Semax. Tolerance means the need to use ever higher doses over time to achieve the same effect – a characteristic feature of many addictive substances.
In studies involving chronic administration for 10–14 days in rats, sustained and progressive behavioural improvements were observed without any signs of decreasing response. The anxiolytic and antidepressant effects appeared to intensify rather than diminish with continued dosing [12].
Semax's neurotrophic mechanism of action, which involves altering gene expression and stimulating the brain's own production of growth factors rather than directly and repeatedly activating a single receptor, is not associated with the receptor downregulation typically driving tolerance development. Receptor downregulation is a process where cells reduce the number of available receptors for a substance when it is constantly present, making the substance gradually less effective.
However, it should be noted that no systematic tolerability studies examining dose-escalation requirements over a prolonged period have been published in humans. A lack of evidence is not the same as evidence of a lack, and this remains a recognised gap in the literature.
Does stopping Semax cause withdrawal symptoms?
No withdrawal symptoms following discontinuation of Semax have been noted in either the clinical or preclinical literature. Withdrawal syndromes arise when the brain has physically adapted to the continuous presence of a substance and struggles to function normally after its abrupt cessation—a phenomenon well-documented with alcohol, benzodiazepines, opioids, and certain stimulants.
The pharmacological profile of Semax – with a relatively short duration of direct receptor activity, lack of direct dopaminergic stimulation, and absence of physical dependence mechanisms – does not predict the occurrence of withdrawal syndrome. Clinical studies using Semax in specific treatment courses – usually 10-day, sometimes repeated – have not described any rebound negative effects after the course completion [13], [14]. Animal studies concerning chronic administration and subsequent behavioural tests after discontinuation also did not report any deterioration below pre-treatment levels.
What happens after stopping Semax?
Based on available evidence, discontinuing Semax does not cause withdrawal symptoms or a decline below baseline. The most likely outcome of ceasing its use is a gradual return to baseline cognitive and neurological functions as its neurotrophic and neuromodulatory effects wear off – however, without the negative rebound effect characteristic of true addictive substance withdrawal.
In the context of post-stroke rehabilitation, beneficial effects on BDNF levels and functional recovery observed during Semax treatment persisted throughout the entire observation period [25], suggesting that at least some of the benefits—particularly those mediated by structural neuroplastic changes induced by a sustained increase in BDNF—may outlive the direct pharmacological activity of the peptide.
The persistence of cognitive improvements observed in spatial memory studies, where the memory-restoring effect was sustained long after the end of a 6-day treatment course [26], further supports the idea that some of Semax's benefits may be self-sustaining through its induced neuroplastic changes, even after the peptide itself is no longer present.
Is Semax detected in doping tests?
No published studies have analysed the detectability of Semax in standard drug tests in urine or blood. Standard screening panels detect specific classes of substances – opioids, stimulants, cannabinoids, benzodiazepines, and cocaine – none of which are structurally related to Semax. A routine workplace drug test would not detect Semax as it is not included in any standard testing panel.
Specialised analytical methods using liquid chromatography coupled with mass spectrometry – an advanced laboratory technique capable of identifying specific molecules at very low concentrations – can detect Semax and Selank in illicit pharmaceutical preparations [27]. This indicates that targeted forensic analysis can identify these peptides when specifically looking for them. Whether any sports, military, or security organisations currently test for Semax is not documented in the peer-reviewed literature. Semax is not listed by the World Anti-Doping Agency (WADA) as a prohibited substance based on available evidence, and no published cases of adverse anti-doping findings related to Semax have been reported.
Can Semax cause cancer or tumour growth?
No published studies have reported tumour growth or cancer promotion with the use of Semax. A study specifically analysing the effect of Semax on spontaneous tumour development in mice found no evidence that the peptide promotes tumour growth [28].
The Semax-induced increase in BDNF warrants theoretical consideration. BDNF signalling through the TrkB receptor has been studied in the context of some cancer types, as BDNF can promote cell survival and growth – properties beneficial in healthy brain tissue, but potentially relevant in cancer biology. However, no direct evidence linking Semax administration to cancer development or progression has been published in any study.
An embryonic stem cell safety study confirmed that Semax did not induce toxic effects and did not dramatically alter stem cell differentiation patterns [16]. This is an important context for understanding its effects on rapidly dividing cells.
The lack of oncogenic signals over decades of Russian clinical use is reassuring. However, formal carcinogenicity studies – specifically designed to test whether a substance can cause cancer with long-term exposure – have not been published for Semax, and this remains a recognised gap in the long-term safety data.
Disclaimer
This article is for educational, informational, and scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a claim regarding the safety or efficacy of Semax for any condition. Semax remains an investigational compound in most countries, including the United States and most European nations, and is not approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and clinically used in Russia and some Eastern European countries. Most of the evidence presented in this paper comes from preclinical animal studies and a limited number of human clinical trials. Additional, well-designed clinical research is needed to more accurately determine the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans.
References
[1] Ashmarin, I. P., Nezavibat'ko, V. N., Miasoedov, N. F., Kamenskii, A. A., Grivennikov, I. A., Ponomareva-Stepnaya, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analogue 4-10-semax (15 years' experience in its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745
[2] Alekseeva, G. V., Bottaev, N. A., & Goroshkova, V. V. (1999). Use of semax in the follow-up of patients with post-hypoxic encephalopathy. Anaesthesiology and Resuscitation, 40–43. PMID: 10199046
[3] Zhuikova, S. E., Smirnova, E. A., Bakaeva, Z. V., Samonina, G. E., & Ashmarin, I. P. (2000). Effect of Semax on homeostasis of gastric mucosa in albino rats. Bulletin of Experimental Biology and Medicine, 130(9), 871–873. PMID: 11177268
[4] Zhuĭkova, S. E., Badmaeva, K. E., Samonina, G. E., & Plesskaia, L. G. (2003). Semax and some glyproline peptides accelerate the healing of acetic ulcers in rats. Experimental and Clinical Gastroenterology, (4), 88–92. PMID: 14653248
[5] Ivanikov, I. O., Brekhova, M. E., Samonina, G. E., Myasoedov, N. F., & Ashmarin, I. P. (2002). Therapy of peptic ulcer with semax peptide. Bulletin of Experimental Biology and Medicine, 134(1), 73–74. https://doi.org/10.1023/a:1020621124776
[6] Gavrilova, S. A., Golubeva, A. V., Lipina, T. V., Fominykh, E. S., Shornikova, M. V., Postnikov, A. B., Andrejeva, L. A., Chentsov, Yu. S., & Koshelev, V. B. (2006). Protective effect of peptide semax on the rat heart after myocardial infarction. Rossiyskiy Fiziologicheskiy Zhurnal imeni I.M. Sechenova, 92(11), 1305–1321. PMID: 17385423
[7] Gorbacheva, A. M., Berdalin, A. B., Stulova, A. N., Nikogosova, A. D., Lin, M. D., Buravkov, S. V., Gavrilova, S. A., & Koshelev, V. B. (2016). Changes in sympathetic innervation of rat caudal artery in experimental myocardial infarction: Effect of Semax peptide. Bulletin of Experimental Biology and Medicine, 161(4), 476–480. https://doi.org/10.1007/s10517-016-3442-y
[8] Grigoryeva, M. E., & Lyapina, L. A. (2010). Anticoagulant and antiplatelet effects of Semax under conditions of acute and chronic immobilisation stress. Bulletin of Experimental Biology and Medicine, 149(1), 44–46. https://doi.org/10.1007/s10517-010-0871-x
[9] Elagina, A. A., Lyashev, Yu. D., Lyashev, A. Yu., Pronyaeva, T. V., & Chahine, A. R. (2020). Correction of lipid metabolism disorders in diabetes mellitus with peptide drugs. Bulletin of Experimental Biology and Medicine, 168(5), 618–620. https://doi.org/10.1007/s10517-020-04764-2
[10] Dontsova, E. V. (2015). Possible drug correction of lipid metabolism disturbances associated with metabolic syndrome in patients with psoriasis. Experimental and Clinical Pharmacology, 78(12), 30–33. PMID: 27051926
[11] Koroleva, M. V., Meĭzerov, E. E., Nezavibat’ko, V. N., Kamenskiĭ, A. A., & Dubynin, V. A. (1996). Effect of the heptapeptide Semax on the human electroencephalogram. Bulletin of Experimental Biology and Medicine, 121(1), 116–117. PMID: 8679991
[12] Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Yu., Kamensky, A. A., Myasoedov, N. F., Levitskaya, N. G., Grivennikov, I. A., & Dolotov, O. V. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogues Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068. https://doi.org/10.1016/j.ejphar.2024.177068
Gusev, E. I., Skvortsova, V. I., & Chukanova, E. I. (2005). Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Journal of Neurology and Psychiatry named after S.S. Korsakov, 105(2), 35–40. PMID: 15792140
[14] Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat’ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of Semax in the acute period of hemispheric ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 97(6), 26–34. PMID: 11517472 https://pubmed.ncbi.nlm.nih.gov/11517472/
[15] Serdiuk, A. V., Levitskiĭ, G. N., Miasoedov, N. F., & Skvortsova, V. I. (2007). The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax. Journal of Neurology and Psychiatry named after S.S. Korsakov, 107(4), 29–39. PMID: 18379501 https://pubmed.ncbi.nlm.nih.gov/18379501/
[16] Kobylyanskii, A. G., Zolotarev, Yu. A., Andreeva, L. A., Grivennikov, I. A., & Myasoedov, N. F. (2017). Studying the toxic effects of some biologically active peptides on the model of mouse embryonic stem cells. Bulletin of Experimental Biology and Medicine, 163(6), 731–736. https://doi.org/10.1007/s10517-017-3891-y
Tomasello, M. F., Di Rosa, M. C., Naletova, I., Sciacca, M. F. M., Giuffrida, A., Maccarrone, G., & Attanasio, F. (2025). Semax, a copper chelator peptide, decreases the Cu(II)-catalysed ROS production and cytotoxicity of Aβ by metal ion stripping and redox silencing. Bioinorganic Chemistry and Applications, 2025, 4226220. https://doi.org/10.1155/bca/4226220
[18] Vilenskiĭ, D. A., Levitskaia, N. G., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2007). Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats. Rossiyskiy Fiziologicheskiy Zhurnal imeni I.M. Sechenova, 93(6), 661–669. PMID: 17850024
[19] Ivanov, A. V., Bobyntsev, I. I., Shepeleva, O. M., Kryukov, A. A., Andreeva, L. A., & Myasoedov, N. F. (2017). Influence of ACTG4-7-PGP (Semax) on the morphofunctional state of hepatocytes in chronic emotional and painful stress. Bulletin of Experimental Biology and Medicine, 163(1), 105–108. https://doi.org/10.1007/s10517-017-3748-4
[20] Bobyntsev, I. I., Shepeleva, O. M., Kryukov, A. A., Ivanov, A. V., & Belykh, A. E. (2015). The effect of peptide ACTH4-7-PGP on functional hepatocyte state in rats in acute and chronic foot-shock stress. Sechenov Physiological Journal, 101(2), 171–179. PMID: 26012109
[21] Svishcheva, M. V., Mishina, Ye. S., Medvedeva, O. A., Bobyntsev, I. I., Mukhina, A. Yu., Kalutskii, P. V., Andreeva, L. A., & Myasoedov, N. F. (2021). Morphofunctional state of the large intestine in rats under conditions of restraint stress and administration of peptide ACTH(4-7)-PGP (Semax). Bulletin of Experimental Biology and Medicine, 170(3), 384–388. https://doi.org/10.1007/s10517-021-05072-z
[22] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
Kost, N. V., Sokolov, O. Yu., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. A., Miasoedov, N. F., & Zozulia, A. A. (2001). Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Organic Chemistry, 27(3), 180–183. https://doi.org/10.1023/a:1011373002885
[24] Liu, R., Chen, Y., Huang, H., Li, X., Lv, J., Jiang, L., Jiang, H., Wu, C., Chen, W., Xu, H., Zhu, Z., Cai, H., Xiao, J., Yin, L., & Ni, W. (2025). Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182(22), 5489–5516. https://doi.org/10.1111/bph.70122
[25] Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
[26] Silachev, D. N., Shram, S. I., Shakova, F. M., Romanova, G. A., & Myasoedov, N. F. (2009). Formation of spatial memory in rats with ischemic lesions to the prefrontal cortex. Neuroscience and Behavioral Physiology, 39(8), 749–756. https://doi.org/10.1007/s11055-009-9197-4
[27] Vanhee, C., Francotte, A., Janvier, S., & Deconinck, E. (2020). The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations. Drug Testing and Analysis, 12(3), 371–381. https://doi.org/10.1002/dta.2717
[28] Meshavkin, V. K., Kost, N. V., Sokolov, O. Yu., Andreeva, L. A., & Myasoedov, N. F. (2013). The influence of oligopeptides on spontaneous carcinogenesis in mice. Doklady Biological Sciences, 449, 79-81. https://doi.org/10.1134/S0012496613020087